Squarepoint’s Keryx Biopharmaceuticals Inc KERX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-57,626
| Closed | -$196K | – | 2435 |
|
|
2018
Q3 | $196K | Buy |
+57,626
| New | +$208K | ﹤0.01% | 1783 |
|
|
2018
Q2 | – | Sell |
-66,812
| Closed | -$273K | – | 2221 |
|
|
2018
Q1 | $273K | Buy |
66,812
+42,664
| +177% | +$199K | ﹤0.01% | 1359 |
|
|
2017
Q4 | $112K | Sell |
24,148
-5,152
| -18% | -$28.4K | ﹤0.01% | 1936 |
|
|
2017
Q3 | $208K | Sell |
29,300
-9,011
| -24% | -$64.8K | ﹤0.01% | 1367 |
|
|
2017
Q2 | $277K | Buy |
38,311
+1,036
| +3% | +$6.47K | 0.01% | 1165 |
|
|
2017
Q1 | $230K | Sell |
37,275
-15,463
| -29% | -$84.7K | 0.01% | 1219 |
|
|
2016
Q4 | $309K | Buy |
+52,738
| New | +$288K | 0.01% | 1140 |
|
|
2016
Q3 | – | Sell |
-40,400
| Closed | -$267K | – | 1400 |
|
|
2016
Q2 | $267K | Sell |
40,400
-21,900
| -35% | -$122K | 0.02% | 786 |
|
|
2016
Q1 | $291K | Sell |
62,300
-17,851
| -22% | -$71.2K | 0.02% | 842 |
|
|
2015
Q4 | $405K | Buy |
+80,151
| New | +$381K | 0.04% | 649 |
|
Squarepoint's KERX Position: Q4 2018 in Review
Squarepoint sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2018, closing a stake of 57,626 shares — an estimated $196K sold.
Squarepoint first reported a position in KERX in Q4 2015 and held it in 10 quarters. The position peaked at $405K in Q4 2015. 1 fund tracked by Wall St. Rank holds KERX as of Q4 2018.
- Squarepoint reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
- Squarepoint sold 57,626 Keryx Biopharmaceuticals Inc shares in Q4 2018, an estimated $196K.
- Squarepoint first reported a position in Keryx Biopharmaceuticals Inc in Q4 2015 and held it in 10 quarters.
- Squarepoint's Keryx Biopharmaceuticals Inc position peaked at $405K in Q4 2015.
- 1 fund tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2018.
Based on Squarepoint's 13F filing for Q4 2018, filed 14 Feb 2019.